Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be…

CFO — Cecile Guegan: The filing announces the permanent appointment of an internal employee (previously Interim CFO) to the role of Chief Financial Officer, which is a succession/promotion event rather than a departure.

Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be…

Regulation FD Disclosure Following the disclosure of Pfizer’s Chief Financial Officer transition announcement on June 18, 2026, Pfizer today is reaffirming its fiscal year 2026 guidance introduced December 16, 2025 and reaffirmed on its first quarter earnings call on May 5, 2026. The company is reaffirming all components of its full-year 2026 guidance previously announced, including Revenues in a range of $59.5 to $62.5 billion and Adjusted Diluted EPS in a Range of $2.80 to $3.00. Additional…

Chief Financial Officer — Dave Denton: Dave Denton is leaving for a professional opportunity outside of the pharmaceutical industry.

Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be…

Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be…

Results of Other Events On November 13, 2025, Pfizer Inc. (“Pfizer” or the “Company”) completed the previously announced acquisition of Metsera, Inc., a Delaware corporation (“Metsera”), pursuant to the Agreement and Plan of Merger, dated as of September 21, 2025, as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated as of November 7, 2025, by and among the Company, Metsera and Mayfair Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (as a…

Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be…

Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be…

Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be…

Cost Associated with Exit or Disposal Activities On April 29, 2025, Pfizer announced approximately $1.2 billion of additional anticipated savings associated with its ongoing cost realignment program (the “Realigning Our Cost Base Program” or the “Program”) expected to be achieved by the end of 2027, designed to further reduce costs primarily in selling, information and administrative expenses (“SI&A”) driven in large part by enhanced digital enablement, including automation and artificial int…

Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be…

Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be…

Director — Mortimer J. Buckley: Mr. Buckley was elected to the Board of Directors and appointed to committees.

Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be…

The filing pertains to modifications in compensatory arrangements and is not related to a management change.

Chief Scientific Officer and President, Pfizer Research & Development — Dr. Mikael Dolsten: The company is beginning the process of finding a successor for Dr. Mikael Dolsten after his more than 15-year distinguished career with the Company.

Director — Cyrus Taraporevala: Mr. Taraporevala was elected to the Board of Directors and appointed to the Audit Committee and Compensation Committee.

Costs Associated with Exit or Disposal Activities In the second quarter of 2024, Pfizer announced it is launching a multi-year program to reduce our cost of goods sold. This cost reduction program (the “program”) will span multiple years, and is expected to include operational efficiencies, network structure changes, and product portfolio enhancements. Given the complexity in manufacturing and longer lead times required to make changes, this program will be a multi-phased effort. The first ph…

Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be…

Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be…

Completion of Acquisition or Disposition of Assets. Pursuant to an Agreement and Plan of Merger (the “ Merger Agreement ”), dated as of March 12, 2023, by and among Pfizer Inc., a Delaware corporation (“ Pfizer ”), Aris Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Pfizer (“ Merger Sub ”), and Seagen Inc., a Delaware corporation (“ Seagen ”), Merger Sub was merged with and into Seagen (the “ Merger ”), with Seagen surviving the Merger as a wholly owned subsidiary of…

Completion of Acquisition or Disposition of Assets. Pursuant to an Agreement and Plan of Merger (the “ Merger Agreement ”), dated as of March 12, 2023, by and among Pfizer Inc., a Delaware corporation (“ Pfizer ”), Aris Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Pfizer (“ Merger Sub ”), and Seagen Inc., a Delaware corporation (“ Seagen ”), Merger Sub was merged with and into Seagen (the “ Merger ”), with Seagen surviving the Merger as a wholly owned subsidiary of…

Regulation FD Disclosure. As previously disclosed, on March 12, 2023, Pfizer entered into an Agreement and Plan of Merger with Seagen, pursuant to which Pfizer will acquire Seagen through a merger (the “Merger”). On December 12, 2023, Pfizer announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired on December 11, 2023. A copy of the press release is attached as Exhibit 99.1 hereto. Pfizer and Seagen have now received all required re…